Clinical Features of Microscopic Polyangiitis: A Cohort Study in a Southern Taiwan Medical Center
|
|
- Magdalen McGee
- 6 years ago
- Views:
Transcription
1 Acta Nephrologica 26(4): 198-5, 12 DOI: /AN.1128 Original Article Clinical Features of Microscopic Polyangiitis: A Cohort Study in a Southern Taiwan Medical Center Chun-Kai Huang 1, 3, Hua-Chang Fang 1, 3, Kang-Ju Chou 1, 3, Jyh-Seng Wang 2, 3, Po-Tsang Lee 1, 3, Tsu-Yuan Chang 1, 3, Chih-Yang Hsu 1, 3, Wei-Chieh Huang 1, 3, Hsiao-Min Chung 1, 3, and Chien-Liang Chen 1, 3 1 Division of Nephrology 2 Division of Pathology, Kaohsiung Veterans General Hospital, Kaohsiung 3 Department of Medicine, National Yang-Ming University, School of Medicine Taipei, Taiwan, Republic of China Abstract BACKGROUND: To determine the clinical features and outcomes of microscopic polyangiitis (MPA) in Taiwanese patients, we retrospectively reviewed the medical records of patients diagnosed with MPA at a single medical center in Taiwan between January 1, 1996 and June 1, 11. METHODS: A cohort of 21 patients (17 men and 4 women) with a mean age of 67 ± 11 years was investigated. Diagnosis was made according to the Chapel Hill criteria for MPA. All patients had renal histological evidence of microscopic polyarteritis. RESULTS: The main clinical manifestations were renal involvement (1%), lung involvement (67%), gastrointestinal involvement (24%), skin lesion (15%), fever (15%), mononeuritis multiplex (1%), and arthralgia (15%). Antineutrophil cytoplasmic antibodies were present in 18 of the 21 patients (86%). Seventeen patients were treated with steroids and cyclophosphamide. Eleven of these 17 patients had stable or improved courses. Ten of the 21 patients (47.6 %) received dialysis at the time of diagnosis and two of them recovered to achieve a dialysis-independent status. Renal survival rates were 46.1% at 1 year and 36.9% at 3 years. A good renal function at diagnosis, lower chronic kidney biopsy index, and good response to treatment were associated with better renal outcome. Patient survival rates were 73.8% at 1 year and 58.7% at 3 years. CONCLUSION: Taiwanese patients with MPA were older, and had a high rate of lung involvement, all of which are indicators of a poor prognosis. Our study suggests that birmingham vasculitis activity score may be a better prognostic predictor in the evaluation of MPA patients. For patients with renal failure, rapid confirmation with renal biopsy and early treatment may improve outcome. KEY WORDS: antineutrophil cytoplasmic antibody, microscopic polyangiitis, vasculitis Introduction Antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) is a multisystem disorder characterized with small-vessel vasculitis and the presence of ANCA. The pathophysiology of AAV is complex involving both the humoral and the cellular immune system. ANCAs promote degranulation of neutrophils and monocytes, thus facilitating endothelial damage (1). The endothelium is also activated and thereby neutrophil adherence is enhanced. The initial damage leads to a cascade of events, resulting Corresponding author: Dr. Chien-Liang Chen, Division of Nephrology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Rd., Kaohsiung 81362, Taiwan, R.O.C. Tel: ext. 219, Fax: , cclchen@seed.net.tw Received: November 3, 11; Revised: May 15, 12; Accepted: July 3, 12. *This work was supported by grants from Kaohsiung Veterans General Hospital (VGHKS1-3). 198
2 Microscopic Polyangiitis in Taiwan 199 in leukocyte tissue infiltration, T-cell-driven granuloma formation, and further damage (2-4). ANCA-associated vasculitis included Wegener granulomatosis, Churg-Strauss syndrome, and microscopic polyangiitis (MPA). MPA was initially recognized as a particular type of polyarteritis nodosa with, in most cases, rapidly progressive necrotizing glomerulonephritis and sometimes with lung hemorrhage (5, 6). In 1994, MPA was distinguished from polyarteritis nodosa by the presence of small-vessel involvement (7). MPA, Wegener granulomatosis, and Churg-Strauss syndrome all involve small vessels and hence share similar clinical features, such as alveolar hemorrhage and rapidly progressive glomerulonephritis. However, unlike Wegener granulomatosis and Churg-Strauss syndrome, MPA does not present granuloma formation or eosinophilia (8). While several studies have investigated the prognosis of ANCA-associated vasculitis, few have discussed MPA specifically as a separate entity. Immunosuppressive therapy in MPA is life- and organsaving and its benefits are widely accepted. However, the toxicity of current regimens remains of concern. While several studies addressed the value of clinical and pathological prognostic factors over the renal outcome, others have reported contradictory results and conclusions (8-12). There is evidence that the prevalence of microscopic polyangiitis, rather than Wegner granulomatosis, is higher in patients of Chinese and Japanese descent compared with that in white patients (13-15). Thus, there may be racial differences in the clinical characteristics of this disease. There has been no research on the clinical features and treatment outcomes of MPA in Taiwanese patients. Therefore, in this study, we characterized and analyzed the clinical manifestations, treatments, and outcomes in a cohort of Taiwanese patients diagnosed with MPA. Materials and Methods We retrospectively reviewed the medical records of 21 patients diagnosed with MPA at Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, between January 1, 1996 and June 1, 11. Diagnoses were made according to the Chapel Hill consensus conference definition of MPA (7), which is based on a renal biopsy showing focal or diffuse segmental crescentic glomerulonephritis (Fig. 1) and a paucity of immunofluorescent immune deposits combined with clinical features. Patients with other smallvessel vasculitides, such as Wegener granulomatosis or Churg-Strauss syndrome, were excluded if they had granulomatosis inflammation, a history of asthma, or anti-glomerular basement membrane antibody. We excluded the patients with possible secondary causes Fig. 1. Microscopic polyangiitis. The Hematoxylin and eosin stained section revealed one glomeruli with fibrocellular crescent and segmental sclerosis. There is significant inflammation in the interstitium. of MPA: malignancy, infection (including hepatitis B and C, HIV, and tuberculosis), and drugs (propylthiouracil, allopurinol, and hydralazine). The date of renal biopsy was used as the starting point of entry into the present study. The end-point for renal survival analysis was the start of long-term renal replacement therapy while that for patient survival was death due to any cause. For each patient, the following data were collected: gender, age, clinical manifestations, laboratory, and immunologic data at the time of diagnosis, treatment, duration of follow-up, and cause of death. The clinical manifestations included symptoms, signs, and organ involvement at presentation. Respiratory involvement was diagnosed on the basis of chest X- rays. Patients who presented severe alveolar hemorrhage requiring ventilator support at the time of diagnosis were considered to have respiratory failure. Cardiomyopathy was defined as significant impairment of cardiac function due to poor ventricular wall motion, confirmed by echocardiography. Laboratory data included white blood cell and platelet counts, hemoglobin, C-reactive protein, blood urea nitrogen, serum creatinine, liver enzyme level, and urinalysis. Proteinuria was defined as the presence of 1 g protein or more in 24-h urinary samples. A clinical diagnosis of rapidly progressive glomerulonephritis was defined as serum creatinine exceeding 4.5 mg/dl at presentation or a two-fold increase in serum creatinine concentration within 3 months of disease onset. Immunologic data included the presence of antinuclear antibody, perinuclear (MPO) and cytoplasmic (PR3) ANCA, antinuclear antibody (ANA), rheumatoid factor (RF), complement components of C3 and C4, hepatitis B virus surface antigen (HBsAg), and antihepatitis C virus antibody (anti-hcv).
3 Huang, Fang, Chou, Wang, Lee, Chang, Hsu, Huang, Chung and Chen The extent of glomerular damage for each patient was assessed by one renal pathologist, and expressed as the percentage of cellular crescents, fibrocellular crescents, fibrous crescents, and global sclerosis. Interstitial fibrosis was graded on a scale of -3 (absent, mild, moderate, and severe). Acute glomerular lesions were cellular and fibrocellular crescents, whereas chronic glomerular lesions were fibrous crescents and global sclerosis. To evaluate the association between disease activity at the time of diagnosis and outcome, we retrospectively applied the Five Factor Score (FFS) (12) and Birmingham Vasculitis Activity Score (BVAS) (16). The FFS is a scoring system based on proteinuria (> 1 g/day), renal insufficiency (serum creatinine > 1.58 mg/dl), severe gastrointestinal (GI) tract involvement (defined as bleeding, perforation, infarction, and/or pancreatitis), cardiomyopathy, and/ or central nervous system (CNS) involvement, with the presence of each factor assigned 1 point. The BVAS evaluation form is divided into nine organbased systems (general, cutaneous, mucous membrane/ eye, ear/nose/throat, chest, cardiovascular, abdominal, and nervous system), with each section comprising symptoms/signs that are typical of that particular organ involvement in systemic vasculitis (16, 17). Clinical renal function improvement during first month was defined as renal function improvement or stable compared with the renal function at diagnosis. Estimated glomerular filtration rate was calculated using the MDRD formula (18). End-stage renal disease (ESRD) was defined as a status in need of maintenance dialysis therapy over 3 months during followup period. Most patients were treated with corticosteroid and cyclophosphamide. Treatment response was defined as attenuation or stabilization of clinical manifestations of MPA and improving serum creatinine level as improvement of kidney function after the first pulse therapy for more than 1 month. Causes of death were classified into three subgroups: vasculitis-related, vasculitis-unrelated such as sepsis, and unknown. Long-term survival of patients was determined by follow-up of their outpatient clinic records and contact with the patients themselves, or their first-degree relatives. Statistical Analyses Kaplan-Meier life survival analysis was employed to assess patient and renal survival. FFS, BVAS, age, plasmapheresis and presence of respiratory failure and ESRD were used as independent variables to predict outcomes using the log-rank test. Age, gender, rapidly progressive glomerulonephritis, blood urea nitrogen, serum creatinine, proteinuria, Table 1. The initial presentation of MPA Number (%) General symptoms (95%) Fever 3 (14%) Malaise 4 (19%) Weight loss 2 (1%) Musculoskeletal 3 (14%) Skin rash 3 (14%) Ear, nose and throat 4 (19%) Gastrointestinal 5 (24%) Abnormal liver function 1 (5%) Severe GI involvement 4 (19%) Cardiac (cardiomyopathy or heart failure) (%) Pulmonary 14 (67%) Alveolar hemorrhage 9 (43%) Pleural effusion 3 (14%) Infiltration or nodule 12 (57%) Renal 21 (1%) Azotemia (>1.58 mg/dl) 21 (1%) Hematuria 21 (1%) Proteinuria (>1 g/24 hr) 19 (9%) Neurologic 2 (1%) Peripheral neuropathy 2 (1%) CNS involvement 1 (5%) acute glomerular lesions, chronic glomerular lesions, and interstitial fibrosis were compared between ESRD and non-esrd groups. Continuous data were analyzed using t-test and nominal data were examined using Fisher s exact test. Statistical significance was defined as P <.5. All statistical analyses were performed using SPSS/Windows software (SPSS, Chicago, IL, 12 versions). Clinical Features Results Of the 21 patients, 17 were men and 4 were women with a mean age of 67 ± 11 years (range, 45-88) at the time of diagnosis. The median duration of follow-up was 18 months (range, 1-182). As seen in Table 1, which summarizes the clinical manifestations at the time of diagnosis and during the course of the disease, the most common features of MPA were renal manifestations (n = 21, 1%) and general symptoms (n =, 95%). Lung involvement was seen in 14 patients (67%). Nine patients presented with alveolar hemorrhage, four of whom needed ventilator support. Laboratory Findings At the time of admission for renal biopsy, the
4 Microscopic Polyangiitis in Taiwan 1 Table 2. Immunologic parameters at the time of diagnosis Positive Number (%) MPO antineutrophil cytoplasmic antibody 18 (86%) Antinuclear antibody 3 (14%) Rheumatoid factor 5 (24%) HBsAg 1 (5%) Anti-HCV 2 (1%) C3 (average ± SD, cutoff: 79~152 mg/dl) 82.1 ± 22.3 C4 (average ± SD, cutoff: 16~38 mg/dl).8 ± 5.1 Unless otherwise indicated, values are frequencies (percentages) or means ± SD. Table 3. Comparison of the clinical features and renal pathology between ESRD and non-esrd patients ESRD (n = 12) non-esrd (n = 9) P value Age (years) 69. ± ± 15.2 NS* Gender (M/F) 1/2 7/2 NS Serum BUN (mg/dl) 85. ± ± Serum creatinine (mg/dl) 7.9 ± ± Proteinuria (g/day) 3.5 ± ± 3.9 NS Acute glomerular lesion (%) 37.2 ± ± 3. NS Chronic glomerular lesion (%) 53. ± ± Interstitial fibrosis scores 1.7 ± ±.8 NS Initial treatment response 2/12 9/9 <.1 *NS: not statistically significant. Active glomerular lesion: cellular and fibrocellular crescents. Chronic glomerular lesion: fibrous crescents and global sclerosis. mean white blood cell and platelet counts were 9.5 ± /µl and 256 ± /µl, respectively. The mean level of hemoglobin was 9.2 ± 1.1 g/dl; C- reactive protein, 6. ± 5.2 mg/dl; blood urea nitrogen, 71. ± 25.7 mg/dl; and serum creatinine, 6.7 ± 2.4 mg/dl. All patients (1%) had renal insufficiency (serum creatinine > 1.5 mg/dl) and active urine sediments of hematuria and proteinuria. Nineteen of the 21 patients (9%) had daily urine protein excretion exceeding 1 gram. Eighteen of the 21 patients were found to be positive for MPO-ANCA, while none were found to have PR3-ANCA (Table 2). Treatment, Outcome and Prognostic Factors Of the 21 patients, 17 (81%) were treated with a combination of steroid and cyclophosphamide. Cyclophosphamide was administered intravenously. One of the 21 patients received steroid treatment only, and the remaining 3 patients received conservative treatment owing to fear of poor response to immunosuppressive treatment and risks of infectious complications. Of the 17 patients treated with steroids and cyclophosphamide, 11 (64.7%) showed stabilization of disease or improvement. Of the 21 patients, 1 (47.6%) needed dialysis therapy within one month after renal biopsy. Two of these dialysis patients, who responded well to pulse steroid and cyclophosphamide therapy, became dialysis-independent. Patients who need longterm renal replacement therapy had more chronic glomerular lesions on pathology, poorer presentation of renal function, and poorer treatment response at initial presentation of disease (Table 3). Seven of the 21 patients (33.3%) died (Table 4) during the follow-up period. The overall MPA mortality was 33.3%. Patient survival rates at one and three years were 73.8% and 58.7%, respectively; while mean and median survival times were 27.8 and 18 months, respectively (Fig. 2A). Renal survival rates at one and three years were 46.1% and 36.9%, while mean and median renal survival times were 15.3 and 3 months, respectively (Fig. 2B). The mean FFS at the time of diagnosis was 2.9 (range, 1-3). As seen in Fig. 3, a depiction of patient survival curves analyzed by FFS, BVAS, age, presence of respiratory failure, entering ESRD and plasmapheresis shows that patients who were older (age > 7 years), entered ESRD, presented with initial respiratory failure, and
5 2 Huang, Fang, Chou, Wang, Lee, Chang, Hsu, Huang, Chung and Chen Table 4. Causes of death in patients with microscopic polyangiitis (n = 7) Number (%) Vasculitis-related Alveolar hemorrhage 1 (14%) Uremia (refused renal replacement therapy) 1 (14%) Vasculitis-unrelated Pneumonia 2 (29%) Other comorbidity-cardiac arrhythmia 1 (14%) Unknown (follow-up loss) 2 (29%) A 1 B 1 6 Renal Survival (%) Fig. 2. Kaplan-Meier renal survival (A) and patient survival curve (B) for the 21 patients with microscopic polyangiitis. had BVAS 22 had poorer outcomes. Discussion Since outcome and recommendations regarding the managements of ANCA-related vasculitis were obtained from Wegener granulomatosis and MPA patients (19-21), caution must be taken when applying these findings to Taiwanese patients, especially since most of them are MPA patients. Although the survival of patients with MPA was not significantly different from that of patients with WG after corrected for age and renal function, there have been no studies focusing on clinical features and treatment outcomes of MPA in Taiwan. This study was to analyze the clinical manifestations, outcomes, and treatments in a cohort of Taiwanese patients using the renal biopsy registry data at our hospital. The analysis revealed that, unlike reports from other countries (Table 5), MPA patients in Taiwan were older at age of onset, male predominant, and more likely to have a positive test for MPO-ANCA, 86% versus 5-% (22-24). The male predominance is compatible with that in previous studies (25-26). Taiwanese patients also have a higher rate of lung involvement. Alveolar hemorrhage was noted in nine patients. However, cardiac involvement and neurological manifestations were less common in our patients. Among our patients, 47.6% were in need of dialysis at the time of diagnosis. Neurological impairment with mononeuritis multiplex was noted in only two patients and one with left pons infarction as initial presentation, suggesting that for patients with nephritis in addition to unexplained stroke or peripheral neuropathy, the diagnosis of systemic vasculitis, such as MPA, should be kept in mind. These patients should be encouraged to receive renal biopsy in order to confirm the diagnosis and begin treatment as early as possible. In one study of Caucasians, ANCA was present at the time of diagnosis in 74.5% of patients, with 64.7% having microscopic polyangiitis for MPO- ANCA and 9.8% positive for PR3-ANCA (12). In
6 Microscopic Polyangiitis in Taiwan 3 A 1 FFS < 3 (n = 17) FFS 3 (n = 4) B 1 BVAS < 22 (n = 16) BVAS 22 (n = 5) C 1 Age < 7 yr (n = 1) Age 7 yr (n = 11) D 1 No respiratory failure (n = 17) Respiratory failure (n = 4) E 1 Not entering ESRD (n = 9) Entering ESRD (n = 12) F 1 No plasmapheresis (n = 12) Receive plasmapheresis (n = 9) Fig. 3. Kaplan-Meier patient survival curves for the 21 patients with microscopic polyangiitis analyzed using the variables of (A) FFS (P =.11), (B) BVAS (P =.7), (C) age, (P =.31), (D) presence of respiratory failure (P =.21), (E) entering ESRD (P =.9) and (F) having received plasmapheresis (P =.17). Data were analyzed using log-rank test.
7 4 Huang, Fang, Chou, Wang, Lee, Chang, Hsu, Huang, Chung and Chen Table 5. Comparison of data from the present study with data from previous reports Manifestations Savage (9) D Agati (1) Adu (11) Guillevin (12) Ahn (25) Present Year Number of patients Mean age(range) 5 (14-73) 49.6 (6-) (16-86) (45-88) Male/female ratio General symptoms Fever 41% 5% 56% 55% 58% 14% Musculoskeletal 72% 67.3% 14% Arthralgia 65% 35% 5% 38% Myalgia 5% 25% 41% 47% Skin rash 35% 53% 62% 51% 14% Ear, nose and throat % 19% Gastrointestinal 56% 3% % 24% Cardiac (cardiomyopathy or heart failure) 9% 18% Pulmonary 55% 34% 25% 42% 67% Pulmonary hemorrhage 29% 12% 7% 43% Pleural effusion 15% 6% 13% 14% Renal 1% 1% 1% 79% 75% 1% Neurologic 44% 1% Peripheral neuropathy 18% 15% 14% 58% % 1% CNS involvement 18% % 12% 9% 5% contrast, 86% of our patients were tested positive for MPO-ANCA and none was positive for PR3-ANCA. The difference between Asians and Caucasians may be related to genetic or environmental factors and requires further studies to clarify our understanding of this variation. Two patients who presented with ESRD at the time of diagnosis needed dialysis therapy. They were treated with pulse steroids and cyclophosphamide and recovered to a dialysis-independent status. A better renal function at diagnosis, a lower chronic kidney injury index and a good response to initial treatment were associated with better renal outcome. Accordingly, once suspicion of systemic vasculitis is apparent, a renal biopsy should be promptly performed to confirm the diagnosis and start immunosuppressive therapy as early as possible. Mortality of vasculitis has been shown to be significantly associated with disease activity, as assessed using the FFS and BVAS (17, 25, 27). This study used the FFS, as an assessment of kidney involvement, severe GI tract involvement, cardiomyopathy, and CNS. However, this scale does not include the pulmonary system. We found that kidney and pulmonary system involvement is more prevalent than GI tract, heart and CNS in our patients, suggesting that this scale may not be suitable for evaluating prognosis of MPA in Taiwanese patients. Conversely, the BVAS, which is more complicated but also more detailed, could be a better predictor of the outcomes. In this study, patients with BVAS above 22 had a poorer prognosis. The overall mortality in our study was 33.3%, similar to that reported previously (26, 28). According to our log-rank tests, the older age at diagnosis was a significant prognostic factor. Respiratory failure was also associated with a poor survival, suggesting that severe lung involvement or alveolar hemorrhage can lead to increased risk of death. The efficacy of plasmapheresis for MPA is unproven. Nine patients received plasmapheresis combined with immunosuppressive therapy. Four of nine patients died later. This plasmapheresis may select patients with severe vasculitis. Further large, randomized studies were needed for further evaluation of the benefits of plasmapheresis. The diagnosis of MPA was made according to a renal biopsy showing focal or diffuse segmental crescentic glomerulonephritis and a paucity of immunofluorescent immune deposits combined with other extra-renal clinical manifestations. This approach may lead to an underestimation of the prevalence of MPA, and select patients with severe renal damage and poorer renal survival. However, despite of this limitation, the inclusion and exclusion criteria allowed for a greater degree of diagnostic specificity and increased the validity of our interpretation of the related data. Furthermore, this is a hospital-based cohort study, implying that selection bias may exist. In conclusion, Taiwanese patients with MPA were older, and had a high rate of lung involvement,
8 Microscopic Polyangiitis in Taiwan 5 all of which are indicators of a poor prognosis. Our study suggests that BVAS may be a better prognostic predictor in the evaluation of MPA patients. For patients with renal failure, rapid confirmation with renal biopsy and early treatment may improve outcome. References 1. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulation and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87: , van Paassen P, Tervaert JWC, Heeringa P. Mechanisms of vasculitis: how pauci-immune is ANCA-associated renal vasculitis? Nephron Exp Nephrol 15: 1-16, Muller Kobold AC, van Wijk RT, Franssen CF, Molema G, Kallenberg CG, Tervaert JW. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener s granulomatosis and microscopic polyangiitis. Clin Exp Rheumatol 17: 433-4, Tervaert JW. Proteinase 3: a cofactor for the binding of antineutrophil cytoplasm antibodies (ANCA) to endothelial cells? Kidney Int 57: ,. 5. Wohlwill F. Über die nur mikroskopisch erkennbare Form der Periarteritis nodosa. Virchows Arch Pathol Anat Physiol 246: 36, Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am 36: , Jennette C, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37: , Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int 56: 87-96, Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 56: , D Agati V, Chander P, Nash M, Mancilla-Jimenez R. Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 7: 95-11, Adu D, Howie AJ, Scott DG, Bacon PA, McGonigle, Michael J. Polyarteritis and the kidney. Q J Med 62: , Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42: , Hattori M, Kurayama H, Koitabashi Y. Japanese society for pediatric nephrology. Antineutrophil cytoplasmic autoantibody associated glomerulonephritis in children. J Am Soc Nephrol 12: , Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology 47: , Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 25: 28-34, Luqmani R, Exley A, Kitas G, Bacon PA. Disease assessment and management of the vasculitides. Bailleres Clin Rheumatol 11: , Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 87: , Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 13: , de Groot K, Adu D, Savage CO, European Vasculitis Study Group (EUVAS). The value of pulse cyclophosphamide in ANCAassociated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16: 18-27, 1.. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al. Determinants of outcome in ANCAassociated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 62: , Tesar V, Ríhová Z, Jancová E, Rysavá R, Merta M. European randomized trials. Current treatment strategies in ANCA-positive renal vasculitis - lessons from European randomized trials. Nephrol Dial Transplant 18 (suppl 5): v2-v4, Pusey CD, Gaskin G. Disease associations with anti-neutrophil cytoplasmic antibodies. Adv Exp Med Biol 336: , Hauschild S, Schmitt WH, Csernok E, Flesch BK, Rautmann A, Gross WL. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 336: , Guillevin L, Visser H, Noel LH, Pourrat J, Vernier I, Gayraud M, et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg- Strauss syndrome 62 patients. J Rheumatol : , Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int 32: , Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmune Rev 9: , Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol 3: , Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology 5: , 11.
ANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationAN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS
GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
More informationEstimating Renal Survival Using the ANCA-Associated GN Classification
Estimating Renal Survival Using the ANCA-Associated GN Classification Marc Hilhorst, Benjamin Wilde, Peter van Breda Vriesman, Pieter van Paassen, and Jan Willem Cohen Tervaert, for the Limburg Renal Registry
More informationVASCULITIS. Case Presentation. Case Presentation
VASCULITIS Case Presentation The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have
More informationCase Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis
Case Presentation VASCULITIS The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have
More informationOlder patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study
Manno et al. BMC Nephrology (2015) 16:88 DOI 10.1186/s12882-015-0082-9 RESEARCH ARTICLE Open Access Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective
More informationImmune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases
Kidney International, Vol. 65 (2004), pp. 2145 2152 Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases MARK HAAS and JOSEPH A. EUSTACE Department of Pathology
More informationSHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth
SHO Teaching Vasculitis Renal medicine Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth OUTLINE What is vasculitis Causes Classification Brief look into ANCA Associated Vasculitis (AAV)
More informationRepeat protocol renal biopsy in ANCA-associated renal vasculitis
NDT Advance Access published February 26, 2014 Nephrol Dial Transplant (2014) 0: 1 5 doi: 10.1093/ndt/gfu042 Original Article Repeat protocol renal biopsy in ANCA-associated renal vasculitis Zdenka Hruskova
More informationVasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis
Edward Dwyer, M.D. Division of Rheumatology VASCULITIS is a primary inflammatory disease process of the vasculature Determinants of the Clinical Manifestations of : Target organ involved Size of vessel
More informationNIH Public Access Author Manuscript Ann Rheum Dis. Author manuscript; available in PMC 2011 July 19.
NIH Public Access Author Manuscript Published in final edited form as: Ann Rheum Dis. 2009 January ; 68(1): 103 106. doi:10.1136/ard.2008.097758. Comparison of disease activity measures for anti-neutrophil
More informationProtocol Version 2.0 Synopsis
Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical
More informationRevised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin
More informationPlasma exchanges in ANCA-associated vasculitis
Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org
More informationCase Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013
Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationRituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
More informationGlucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Article Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick
More informationVasculitis of the peripheral nervous system
4 rd Congress of the European Academy of Neurology Lisbon, Portugal, June 16-19, 2018 Teaching Course 5 Acute emergencies in neuromuscular disease - Level 2 Vasculitis of the peripheral nervous system
More informationSmall Vessel Vasculitis
Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk
More informationPAEDIATRIC VASCULITIS
PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationOptimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials
Prague Medical Report / Vol. 107 (2006) No. 2, p. 199 212 199) Optimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials Vaňková
More informationVasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura)
Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura) J. Charles Jennette Ronald J. Falk The kidneys are affected by a variety of systemic vasculitides
More informationfor the European Vasculitis Study Group submitted
Predictors of long-term ( 5 year) renal survival in 55 patients with ANCA-associated vasculitis Annelies Berden Oliver Floßmann Kerstin Westman Peter Höglund Chris Hagen Saskia le Cessie Michael Walsh
More informationLong-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange: a retrospective, single-centre study
Frausová et al. Arthritis Research & Therapy (2016) 18:168 DOI 10.1186/s13075-016-1055-5 RESEARCH ARTICLE Open Access Long-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange:
More informationRenal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis
Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis E.S. Park, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee Division of Rheumatology, Department of Internal
More informationPauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters?
International Journal of Rheumatic Diseases 2016; 19: 74 81 ORIGINAL ARTICLE Pauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters? Aman SHARMA, 1, * Ritambra
More informationManagement of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe
Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction
More informationRATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with
http://www.kidney-international.org chapter 13 & 2012 KDIGO Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis Kidney International Supplements (2012) 2, 233 239; doi:10.1038/kisup.2012.26
More informationANCA-associated vasculitis with renal involvement: an outcome analysis
NDT Advance Access published April 6, Nephrol Dial Transplant () 1 of 9 DOI: 1.193/ndt/gfh161 Original Article ANCA-associated vasculitis with renal involvement: an outcome analysis Sven Weidner 1, Steffen
More informationDr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Vasculitis Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Disease Spectrum Hypersensitivity vasculitis/microscopic
More informationManaging Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
More informationAtlas of the Vasculitic Syndromes
CHAPTER e40 Atlas of the Vasculitic Syndromes Carol A. Langford Anthony S. Fauci Diagnosis of the vasculitic syndromes is usually based upon characteristic histologic or arteriographic findings in a patient
More informationV asculitis is an inflammatory process of blood vessels,
723 ORIGINAL ARTICLE Cinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre
More informationDual positive serology in a case of rapidly progressive glomerulonephritis in a middle aged woman
CASE REPORT Advance Access publication 20 May 2014 Dual positive serology in a case of rapidly progressive glomerulonephritis in a middle aged woman Rubina Naqvi 1, Muhammed Mubarak 2 1 Department of Nephrology
More informationAnnals of the Rheumatic Diseases 2011; 70(3):
Long-term patient survival in ANCA-associated vasculitis Oliver Floßmann Annelies Berden Kirsten de Groot Chris Hagen Lorraine Harper Caroline Heijl Peter Höglund David Jayne Raashid Luqmani Alfred Mahr
More informationEDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link
EDITORIAL, October 2004 Welcome to the Spring 2004 Edition of InfoLink. The feature article in this edition has been written by Dr Rodger Laurent, Head of Department, PaLMS Rheumatology Laboratory. The
More informationDecember 6, 2010 Asthma and Rheumatic Disorders and Vasculitis
December 6, 2010 Asthma and Rheumatic Disorders and Vasculitis Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated 2- infectious
More informationElevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis
Original Article Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis Huijuan Wang, Chao Zhang, Zhaohui Tong, Xiaoning Bu Department
More informationCrescentic Glomerulonephritis (RPGN)
Crescentic Glomerulonephritis (RPGN) Background Rapidly progressive glomerulonephritis (RPGN) is defined as any glomerular disease characterized by extensive crescents (usually >50%) as the principal histologic
More informationanti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
More informationAnti-neutrophil Cytoplasmic Antibody-associated Pauci-immune Crescentic Glomerulonephritis Complicating Sjögren s Syndrome
Volume 110 Number 7 July 2011 Enterovirus 71 vaccine: When will it be available? GRP78 in embryonic development and neurological disorders Directly observed therapy for Tuberculosis patients in Taiwan
More informationElevated Expression of Pentraxin 3 in Anti-neutrophil Cytoplasmic Antibody-associated Glomerulonephritis with Normal Serum C-reactive Protein
CASE REPORT Elevated Expression of Pentraxin 3 in Anti-neutrophil Cytoplasmic Antibody-associated Glomerulonephritis with Normal Serum C-reactive Protein Risa Ishida 1,KentaroNakai 1, Hideki Fujii 1, Shunsuke
More informationClinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
More informationINTRODUCTION. nephropathy, however, usually presents as membranoproliferative
Hong Kong J Journal Nephrol of 2001;3(2):97-102. Nephrology 2001;3(2):97-102. A KURUSU, et al C A S E R E P O R T Monitoring of serum hepatitis C virus RNA level during steroid therapy for hepatitis C
More informationAntineutrophil cytoplasmic antibody (ANCA) associated. Article
Annals of Internal Medicine Article Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody Associated Small-Vessel Vasculitis Susan L. Hogan, PhD, MPH; Ronald J. Falk, MD;
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationCitation for published version (APA): Chen, M. (2009). Pathogenetic and clinical aspects of ANCA-associated vasculitis Groningen: s.n.
University of Groningen Pathogenetic and clinical aspects of ANCA-associated vasculitis Chen, Min IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated inflammation
More informationPresenting Features in Pakistani Patients Suffering from the Antineutrophil Cytoplasmic Antibody - Classical Subtype (c- ANCA) Associated Vasculitis
Presenting Features in Pakistani Patients Suffering from the Antineutrophil Cytoplasmic Antibody - Classical Subtype (c- ANCA) Associated Vasculitis Tahir Aziz Ahmed,Abdul Halim,Tassawar Hussain,Nadeem
More informationSmall Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
More informationPersistent hematuria in patients with. vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?
Lv et al. BMC Nephrology (2017) 18:354 DOI 10.1186/s12882-017-0763-7 RESEARCH ARTICLE Open Access Persistent hematuria in patients with antineutrophil cytoplasmic antibodyassociated vasculitis during clinical
More informationDiagnostic Procedures for Vasculitis
Diagnostic Procedures for Vasculitis Toshiharu Matsumoto, MD Clinical Professor of Department of Diagnostic Pathology Juntendo University Nerima Hospital, Tokyo, Japan Introduction In 1994, the International
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Rituximab for treatment of severe renal disease in ANCA associated vasculitis Geetha, Duvuru; Hruskova, Zdenka; Segelmark, Marten; Hogan, Jonathan; Morgan, Matthew; Cavero, Teresa; Eriksson, Per; Seo,
More informationApproach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis
GLOMERULONEPHRITIDES Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis Heavy Proteinuria Renal failure Low serum Albumin Hypertension
More informationWegener s Granulomatosis JUN-KI PARK
Wegener s Granulomatosis JUN-KI PARK Definition History Epidemiology Clinical symptoms Pathophysiology Treatment Wegener granulomatosis (WG) is a complex, immunemediated disorder, which along with microscopic
More informationCitation for published version (APA): Chen, M. (2009). Pathogenetic and clinical aspects of ANCA-associated vasculitis Groningen: s.n.
University of Groningen Pathogenetic and clinical aspects of ANCA-associated vasculitis Chen, Min IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationRate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis M. Jung 1, L. Barra 2 1 Division of Rheumatology, Department of Medicine, University
More information4. KIDNEYS AND AUTOIMMUNE DISEASE
How to Cite this article: Kidneys and Autoimmune Disease - ejifcc 20/01 2009 http://www.ifcc.org 4. KIDNEYS AND AUTOIMMUNE DISEASE Maksimiljan Gorenjak 4.1 Autoimmune diseases The human immune system limits
More informationPredictors of renal and patient outcomes in anti-gbm disease: clinicopathologic analysis of a two-centre cohort
NDT Advance Access published January 20, 2015 Nephrol Dial Transplant (2015) 0: 1 7 doi: 10.1093/ndt/gfu399 Original Article Predictors of renal and patient outcomes in anti-gbm disease: clinicopathologic
More informationANCA-associated glomerulonephritis in the very elderly
http://www.kidney-international.org & 2011 International Society of Nephrology original article see commentary on page 699 ANCA-associated glomerulonephritis in the very elderly Andrew S. Bomback 1, Gerald
More informationEarly plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis
Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis J.W. Gregersen 1, T. Kristensen 1, S.R.P. Krag 2, H. Birn 1, P. Ivarsen 1 1 Department of Nephrology, 2 Department of Pathology,
More informationEnd-stage renal disease in ANCA-associated vasculitis
Nephrol Dial Transplant (2017) 32: 248 253 doi: 10.1093/ndt/gfw046 Advance Access publication 6 April 2016 End-stage renal disease in ANCA-associated vasculitis Sergey Moiseev 1, Pavel Novikov 1, David
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationReview Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar
Review Article Vidarbha Journal of Internal Medicine Volume 23 July 207 Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis Milind Aurangabadkar ABSTRACT Anti-neutrophil
More informationLong-term follow-up of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
http://www.kidney-international.org & 2013 International Society of Nephrology Long-term of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment
More informationRAPIDLY FAILING KIDNEYS. Dr Paul Johny 2 nd yr DNB Medicine Resident
RAPIDLY FAILING KIDNEYS Dr Paul Johny 2 nd yr DNB Medicine Resident Mr Z 67yrs old Occupation : Retired officer from electricity board Chief complaints : Fever : 5 days Right lower limb swelling and pain
More informationTreatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2015;41:296301 Received: March 12, 2015 Accepted: May 6, 2015 Published online: June 2, 2015 Treatment
More informationCase Report Hydralazine Induces Myeloperoxidase and Proteinase 3 Anti-Neutrophil Cytoplasmic Antibody Vasculitis and Leads to Pulmonary Renal Syndrome
Case Reports in Nephrology, Article ID 868590, 4 pages http://dx.doi.org/10.1155/2014/868590 Case Report Hydralazine Induces Myeloperoxidase and Proteinase 3 Anti-Neutrophil Cytoplasmic Antibody Vasculitis
More informationA clinical syndrome, composed mainly of:
Nephritic syndrome We will discuss: 1)Nephritic syndrome: -Acute postinfectious (poststreptococcal) GN -IgA nephropathy -Hereditary nephritis 2)Rapidly progressive GN (RPGN) A clinical syndrome, composed
More informationClinical characteristics and outcome of vasculitides
GENERAL SECTION ORIGINAL ARTICLE Clinical characteristics and outcome of vasculitides Buddhi Prasad Paudyal, 1 Madhu Gyawalee 2 ISSN: 2091-2749 (Print) 2091-2757 (Online) Correspondence Dr. Buddhi Prasad
More informationTHE URINARY SYSTEM. The cases we will cover are:
THE URINARY SYSTEM The focus of this week s lab will be pathology of the urinary system. Diseases of the kidney can be broken down into diseases that affect the glomeruli, tubules, interstitium, and blood
More informationMohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward
VASCULITIS SYNDROMES Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward ILLUSTRATED CASE 1 A 56 years old lady refered me for prolonged fever, arthritis
More informationTHE URINARY SYSTEM. The cases we will cover are:
THE URINARY SYSTEM The focus of this week s lab will be pathology of the urinary system. Diseases of the kidney can be broken down into diseases that affect the glomeruli, tubules, interstitium, and blood
More informationSMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
More informationDisease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia
International Journal of Clinical Rheumatology Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia Background: ANCA-associated vasculitis (AAV) is a potentially
More informationCASE REPORT. Abstract. Introduction. Case Reports
CASE REPORT Efficacy of Early Intravenous Immunoglobulin for Eosinophilic Granulomatosis with Polyangiitis with Drastically Progressive Neuropathy: A Synopsis of Two Cases Takeshi Matsumoto 1, Kojiro Otsuka
More informationCASE REPORT. Introduction
doi: 10.2169/internalmedicine.9188-17 http://internmed.jp CASE REPORT Diffuse Alveolar Hemorrhage Developing Immediately after Immunosuppressive Treatments in a Patient with Granulomatosis with Polyangiitis
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationCase Report Crescentic Glomerulonephritis with Anti-GBM and p-anca Antibodies
Case Reports in Nephrology Volume 2012, Article ID 132085, 4 pages doi:10.1155/2012/132085 Case Report Crescentic Glomerulonephritis with Anti-GBM and p-anca Antibodies TariqJavedandParagVohra Department
More informationImproved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies
Nephrol Dial Transplant (2015) 30: i67 i75 doi: 10.1093/ndt/gfv008 Advance Access publication 17 February 2015 Original Article Improved prognosis in Norwegian patients with glomerulonephritis associated
More informationANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,
More informationRelation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
Houben et al. BMC Nephrology (2017) 18:378 DOI 10.1186/s12882-017-0797-x RESEARCH ARTICLE Open Access Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis Eline
More informationThe systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.
60 Treatment of ANCA-associated Systemic Vasculitis H. Michael Belmont, M.D. Abstract The antineutrophil cytoplasmic antibodies (ANCA)-associated small vessel vasculitides include Wegener s granulomatosis,
More information29 Glomerular disease: an overview
29 Glomerular : an overview Renal Extra-renal Neurological changes Clinical syndromes pressure Sore throat (streptococcal) Rash Cardiac valve lesions Hemoptysis Asymptomatic or Acute Glomerulonephritis
More informationClinical features and outcome of patients with both ANCA and anti-gbm antibodies
Kidney International, Vol. 66 (24), pp. 1535 154 Clinical features and outcome of patients with both ANCA and anti-gbm antibodies JEREMY B. LEVY, TARIG HAMMAD, ANNE COULTHART, TAMMY DOUGAN, and CHARLES
More informationCase 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016
Case 3 Lynn D. Cornell, M.D. Mayo Clinic, Rochester, MN Cornell.Lynn@mayo.edu USCAP Renal Case Conference March 13, 2016 ACCME/Disclosure Dr. Cornell has nothing to disclose Clinical history 57-year-old
More informationLong-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
Rheumatology 2008;47:1515 1520 Advance Access publication 1 August 2008 doi:10.1093/rheumatology/ken321 Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated
More informationThe European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France
The European and French networks Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France French Vasculitis Study Group December 1980: L. Guillevin no research,
More informationChapter 2 Animal Models of ANCA-Associated Vasculitides
Chapter 2 Animal Models of ANCA-Associated Vasculitides Domenico Ribatti and Franco Dammacco Abstract Antibodies against neutrophil proteins myeloperoxidase (MPO) and proteinase- 3 (PR3) are responsible
More informationGlomerular diseases mostly presenting with Nephritic syndrome
Glomerular diseases mostly presenting with Nephritic syndrome 1 The Nephritic Syndrome Pathogenesis: proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls escape of RBCs
More informationCirculating complement activation in patients with anti-neutrophil cytoplasmic antibody associated vasculitis
http://www.kidney-international.org & 212 International Society of Nephrology see commentary on page 16 Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody associated
More informationVCRC-OMERACT ANCA-Vasculitis Outcome Measure Initiative Comparative Outcome Measure Exercise-Training Cases
Introduction to Training Cases The purpose of this preliminary exercise is to familiarize you with the rules and logistics of the five instruments under study. Please do not read the Training Cases until
More informationRenal transplantation
NEPHROLOGY 2008; 13, S37 S43 doi:10.1111/j.1440-1797.2008.00996.x Renal transplantation Date written: November 2006 Final submission: July 2007 Author: Nigel Toussaint GUIDELINES No recommendations possible
More informationANTI NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) TESTING GUIDELINES
ANTI NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) TESTING GUIDELINES Version: 1.0 Ratified by: Clinical Biochemistry Senior Staff Group Date ratified: Name of originator/author: Director responsible for implementation:
More informationClinical analysis of nervous system involvement in ANCA-associated systemic vasculitides
Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides W. Zhang, G. Zhou*, Q. Shi, X. Zhang, X.-F. Zeng, F.-C. Zhang Department of Rheumatology, Peking Union Medical College
More informationW J N. World Journal of Nephrology. Antineutrophil cytoplasmic antibodies crescentic allograft glomerulonephritis after sofosbuvir therapy.
W J N World Journal of Nephrology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v5.i6.547 World J Nephrol 2016 November 6; 5(6):
More informationLong-term Prognosis of Anti-Neutrophil Cytoplasmic Antibody- Negative Renal Vasculitis: Cohort Study in Korea
ORIGINAL ARTICLE Nephrology http://dx.doi.org/10.3346/jkms.2016.31.4.542 J Korean Med Sci 2016; 31: 542-546 Long-term Prognosis of Anti-Neutrophil Cytoplasmic Antibody- Negative Renal Vasculitis: Cohort
More information